SOURCE: FluoroPharma Medical, Inc.

September 04, 2012 08:00 ET

FluoroPharma to Present at the Rodman & Renshaw Annual Global Investment Conference

MONTCLAIR, NJ--(Marketwire - Sep 4, 2012) - FluoroPharma Medical, Inc. (OTCBB: FPMI) (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that Thijs Spoor, President & CEO of FluoroPharma Medical, will present at the Rodman & Renshaw Annual Global Investment Conference, to be held at the Waldorf Astoria from September 9th through September 11th in New York City.

Mr. Spoor's formal presentation is scheduled for Tuesday, September 11th at 10:50AM ET. In addition, Mr. Spoor will be available for separate one-on-one meetings throughout the day on Tuesday, and on Monday, September 10th.

At the time of the presentation, a live audio and high-definition video webcast of FluoroPharma Medical's presentation and a copy of the presentation materials will be available on the investor relations page on the Company's website

About FluoroPharma Medical

FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The Company has licensed technology from the Massachusetts General Hospital in Boston.

The Company's goal is to enable personalized medicine through advanced imaging products that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes.

The Company's initial focus is the development of breakthrough positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). FluoroPharma is advancing two products in clinical trials for assessment of acute and chronic forms of coronary disease. These first in class agents have been designed to rapidly target myocardial cells. Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, agents with the potential to image Alzheimer's disease and agents that could potentially be used for imaging specific cancers.

For more information on the Company, please visit:

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward looking statements in this news release include statements regarding FluoroPharma's research and development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in FluoroPharma's filings with the United States Securities and Exchange Commission. FluoroPharma undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

    Investor Relations:
    Richard Moyer
    Cameron Associates, Inc.
    Email Contact
    Phone: 212-554-5466

    Carol J. Perlman
    FluoroPharma Medical, Inc.
    Email Contact
    Phone: 917-592-9260